Day: March 26, 2026

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations Received Gross Proceeds of $90 Million in Private Placement Financing of Common Stock and Warrants with Cash-Exercisable Warrants Potentially Providing up to an Additional $146 Million to Support Development of Lasofoxifene Through Key Clinical and Regulatory Milestones Expect to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026 BOTHELL, Wash., March 26, 2026 (GLOBE NEWSWIRE) — LeonaBio,...

Company Demonstrates Clinical Validation and Early Commercial Traction Toward 2026 Revenue Scale RA’ANANA, Israel, March 26, 2026 (GLOBE NEWSWIRE) — Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2025, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: “2025 marked a pivotal year for Inspira as we advanced from clinical validation into early commercial execution. Throughout 2025 and since year-end, we saw meaningful progress across multiple commercialization pathways for the INSPIRA™ ART100 system, including active clinical use at leading medical centers, advancement of...

Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026. Single preclinical administration of semaglutide implant configuration demonstrates continued semaglutide exposure and >20% sham-adjusted weight loss for a full year. Solid cash position from multiple recent financings will support operations into mid-2027 and enable the projected completion of key milestones including the Phase 1 study of NPM-139. ALAMEDA, Calif., March 26, 2026 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing...

Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market. This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial and...

HAUPPAUGE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (NASDAQ: AMPG) today reported financial results for the fiscal year ended December 31, 2025, as included in its Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. Strong Revenue Growth Driven by 5G and Core RF Product Demand Revenue increased to $25.2 million for fiscal year 2025, compared to $9.5 million in fiscal year 2024, representing growth of approximately 165% year-over-year. The increase was driven primarily by higher sales of low noise amplifier (LNA) and low noise block (LNB) products, expanded 5G product lines, and strong demand from telecommunications and satellite communications customers. The Spectrum division also benefited from a rebound in Asian markets. Gross Profit Expansion Reflects Strategic 5G Market Penetration Gross...

Delivered first production powertrains for Blue Bird school buses Achieved third consecutive quarter of positive operating cash flow and free cash flow, ending 2025 with $14.0 million in cash — up 28% year-over-year Reduced full-year operating expenses by $14.0 million (28.2% YoY) and cut full-year EBITDA loss by more than half — from $42.2 million to $21.0 million LOS ANGELES, March 26, 2026 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leading energy storage and fleet electrification solutions provider, today reported financial results for the fourth quarter and full year ended December 31, 2025. Building on a year of disciplined execution and consistent operational improvement, Xos closed 2025 with its third consecutive quarter of positive operating cash flow and positive free...